Barclays analyst Gena Wang raised the firm’s price target on Cellectis (CLLS) to $8 from $4 and keeps an Overweight rating on the shares. The company’s research and development day provided updates on lasme-cel’s “promising” efficacy data, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLLS: